logo
Plus   Neg
Share
Email

Regeneron, Sanofi: European Commission Approves New Indication For Dupixent

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Commission has approved a new indication for Dupixent in chronic rhinosinusitis with nasal polyposis. Dupixent is now approved in the EU for three type 2 inflammatory diseases: severe chronic rhinosinusitis with nasal polyposis, severe asthma and moderate-to-severe atopic dermatitis.

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13 proteins. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. Dupixent was invented using Regeneron's VelocImmune technology, which uses a genetically-humanized mouse to produce optimized fully-human antibodies.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT